https://www.selleckchem.com/products/en460.html
65, 95%confidence interval [CI] 1.08-2.53), β-blocker side-effects (HR=2.69, 95%CI 1.75-4.13), and psychiatric disease (HR=1.63, 95%CI 1.04-2.57). By contrast, patients presenting with ventricular tachycardia/syncope as cLQTS disease manifestation were less likely to have a treatment break compared with asymptomatic patients (HR=0.55, 95%CI 0.33-0.82). Reduced β-blocker adherence was common with more than a third of patients having a treatment break 60days after cLQTS diagnosis. Patients with psychiatric disease, self-reported β-block